20.500.12556/DiRROS-19804 Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma Background. Drug-eluting microsphere transarterial chemoembolization (DEM-TACE) is the standard of care in pa-tients with intermediate-stage hepatocellular carcinoma and ensures targeted and controlled cytotoxic and ischemic effects. Proper patient selection and optimized treatment techniques are associated with longer median survival. The aim of this single-institution retrospective study was to evaluate safety and efficacy of DEM-TACE under cone beam computed tomography (CBCT) control in patients with early and intermediate stagehepatocellular carcinoma.Patients and methods. A total of144 patients (mean age 67.9 ± 8.0 years, 127 males and 17 females) between February 2010 and December 2018 were studied. Microparticles of different dimensions according to two manufac-turers (diameter of 70–150 μm, 100–300 μm or 300–500 μm and 40-μm, 75-μm or 100-μm) were used and loaded with 50–150 mg of doxorubicin. The objective tumour response according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST), the time to progression, adverse events and overall survival were (OS) evaluated.Results. In total, 452 procedures were performed (median, 3 per patient). Four (0.9% of all procedures) major com-plications were noted. Postembolization syndrome occurred after 35% of procedures. At the first imaging follow-up 2–3 months after first treatment, 91% of patients achieved an objective response. The median time to progression was 10.2 months (95% CI: 8.3-12.1 months). OS rates at 1, 2, 3, 4, and 5 years were 85%, 53%, 33%, 20% and 14%, respectively. The median survival time was 25.8 months (95% CI: 22.1–29.5 months). Conclusions. DEM-TACE under CBCT control in patients with early and intermediate stagehepatocellular carcinoma is a safe and effective method of treatment with high objective tumour response and survival rates. hepatocellular carcinoma drug-eluting microspheres doxorubicin hepatocelularni karcinom mikrosfere doksorubicin true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-07-25 09:05:13 2024-07-25 09:05:14 2024-07-26 04:28:36 0000-00-00 00:00:00 2022 0 0 Soavtorji: Nastja Levasic, Rok Dezman, Lara Anja Lesnik Zupan, Blaz Trotovsek, Rado Jansa, Alojz Smid, Peter Popovic; str. 311-318 iss. 3 Vol. 56 Sep. 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2022-09-01 616.36:616-006 1318-2099 10.2478/raon-2022-0019 122441987 https://www.radioloncol.com/index.php/ro/article/view/3820/5082 1 7b97bb89-4a43-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=27429 RAZ_Korsic_Spela_2022.pdf RAZ_Korsic_Spela_2022.pdf 1 3431A80EEBD70EEFBE466DDC6D4D57F7 c728037ce1044d459b96730cac8311ca28349064e3abc85b0d3b2aa4a0d89a9c a0cddea0-4a43-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=27430 Onkološki inštitut Ljubljana 0 0 0